Substance / Medication

Oxamniquine

Overview

Active Ingredient
oxamniquine
RxNorm CUI
7778

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

8 trials linked to this intervention

8
Total Trials
2
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Treatment of human acute schistosomiasis with oxamniquine induces an increase in interferon-gamma response to Schistosoma mansoni antigens.
de Souza Joelma R, Morais Clarice N L, Aroucha Marcílio L et al. · Mem Inst Oswaldo Cruz · 2007
PMID: 17426890Observational
Large CRISPR-Cas-induced deletions in the oxamniquine resistance locus of the human parasite.
Sankaranarayanan Geetha, Coghlan Avril, Driguez Patrick et al. · Wellcome Open Res · 2020
PMID: 32789192OtherFull text (PMC)
Structural Mechanisms Driving the Selective Efficacy of Oxamniquine against Schistosoma mansoni and Schistosoma japonicum.
Paul-Odeniran Kehinde F, Iwuchukwu Emmanuel A, Odeniran Paul O · Cell Biochem Biophys · 2025
PMID: 40251361PreclinicalFull text (PMC)
Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments.
Toth Katalin, Alwan Sevan, Khan Susan et al. · Int J Parasitol Drugs Drug Resist · 2023
PMID: 36758271PreclinicalFull text (PMC)
Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis.
Alwan Sevan N, Taylor Alexander B, Rhodes Jayce et al. · PLoS Pathog · 2023
PMID: 37428793PreclinicalFull text (PMC)
Multidisciplinary Preclinical Investigations on Three Oxamniquine Analogues as New Drug Candidates for Schistosomiasis*.
Buchter Valentin, Ong Yih Ching, Mouvet François et al. · Chemistry · 2020
PMID: 32852116Preclinical
Schistosomal Sulfotransferase Interaction with Oxamniquine Involves Hybrid Mechanism of Induced-fit and Conformational Selection.
Ezebuo Fortunatus C, Uzochukwu Ikemefuna C · Curr Comput Aided Drug Des · 2020
PMID: 31284869Preclinical
An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans.
Guzman Meghan A, Rugel Anastasia R, Tarpley Reid S et al. · PLoS Negl Trop Dis · 2020
PMID: 32810153PreclinicalFull text (PMC)
Why does oxamniquine kill Schistosoma mansoni and not S. haematobium and S. japonicum?
Rugel Anastasia R, Guzman Meghan A, Taylor Alexander B et al. · Int J Parasitol Drugs Drug Resist · 2020
PMID: 32315953PreclinicalFull text (PMC)
Oxamniquine resistance alleles are widespread in Old World Schistosoma mansoni and predate drug deployment.
Chevalier Frédéric D, Le Clec'h Winka, McDew-White Marina et al. · PLoS Pathog · 2019
PMID: 31652296PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Oxamniquine (substance)
SNOMED CT
747006
UMLS CUI
C0029994
RxNorm CUI
7778

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
8
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.